nodes	percent_of_prediction	percent_of_DWPC	metapath
Duloxetine—Suicide attempt—Lamivudine—hepatitis B	0.00839	0.00842	CcSEcCtD
Duloxetine—Hepatic failure—Entecavir—hepatitis B	0.0083	0.00834	CcSEcCtD
Duloxetine—Hypertriglyceridaemia—Lamivudine—hepatitis B	0.00829	0.00832	CcSEcCtD
Duloxetine—Influenza like illness—Telbivudine—hepatitis B	0.0082	0.00824	CcSEcCtD
Duloxetine—Hepatic failure—Adefovir Dipivoxil—hepatitis B	0.0081	0.00814	CcSEcCtD
Duloxetine—Completed suicide—Lamivudine—hepatitis B	0.00809	0.00813	CcSEcCtD
Duloxetine—Renal impairment—Adefovir Dipivoxil—hepatitis B	0.00765	0.00768	CcSEcCtD
Duloxetine—Blood triglycerides increased—Lamivudine—hepatitis B	0.00726	0.0073	CcSEcCtD
Duloxetine—Blood creatinine increased—Entecavir—hepatitis B	0.00699	0.00702	CcSEcCtD
Duloxetine—Blood creatine phosphokinase increased—Lamivudine—hepatitis B	0.00691	0.00695	CcSEcCtD
Duloxetine—Blood creatinine increased—Adefovir Dipivoxil—hepatitis B	0.00682	0.00685	CcSEcCtD
Duloxetine—Abdominal pain upper—Entecavir—hepatitis B	0.00681	0.00685	CcSEcCtD
Duloxetine—Liver function test abnormal—Adefovir Dipivoxil—hepatitis B	0.00672	0.00675	CcSEcCtD
Duloxetine—Renal impairment—Telbivudine—hepatitis B	0.00644	0.00647	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Adefovir Dipivoxil—hepatitis B	0.00642	0.00645	CcSEcCtD
Duloxetine—Pancreatitis—Entecavir—hepatitis B	0.00632	0.00635	CcSEcCtD
Duloxetine—Pancreatitis—Adefovir Dipivoxil—hepatitis B	0.00617	0.0062	CcSEcCtD
Duloxetine—Pain in extremity—Telbivudine—hepatitis B	0.00613	0.00616	CcSEcCtD
Duloxetine—Migraine—Telbivudine—hepatitis B	0.00603	0.00606	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Entecavir—hepatitis B	0.00599	0.00602	CcSEcCtD
Duloxetine—Hyperglycaemia—Entecavir—hepatitis B	0.00582	0.00584	CcSEcCtD
Duloxetine—Blood disorder—Lamivudine—hepatitis B	0.0057	0.00572	CcSEcCtD
Duloxetine—Weight decreased—Adefovir Dipivoxil—hepatitis B	0.00569	0.00572	CcSEcCtD
Duloxetine—Renal failure—Entecavir—hepatitis B	0.00565	0.00568	CcSEcCtD
Duloxetine—Abdominal pain upper—Telbivudine—hepatitis B	0.0056	0.00562	CcSEcCtD
Duloxetine—Aspartate aminotransferase increased—Telbivudine—hepatitis B	0.00552	0.00554	CcSEcCtD
Duloxetine—Cramp muscle—Telbivudine—hepatitis B	0.00552	0.00554	CcSEcCtD
Duloxetine—Renal failure—Adefovir Dipivoxil—hepatitis B	0.00551	0.00554	CcSEcCtD
Duloxetine—Nasopharyngitis—Telbivudine—hepatitis B	0.00548	0.00551	CcSEcCtD
Duloxetine—Jaundice—Adefovir Dipivoxil—hepatitis B	0.00547	0.00549	CcSEcCtD
Duloxetine—Hepatobiliary disease—Entecavir—hepatitis B	0.00544	0.00546	CcSEcCtD
Duloxetine—Gastritis—Telbivudine—hepatitis B	0.00542	0.00545	CcSEcCtD
Duloxetine—Muscular weakness—Telbivudine—hepatitis B	0.00541	0.00543	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Telbivudine—hepatitis B	0.00541	0.00543	CcSEcCtD
Duloxetine—Rhabdomyolysis—Lamivudine—hepatitis B	0.00538	0.0054	CcSEcCtD
Duloxetine—Hepatobiliary disease—Adefovir Dipivoxil—hepatitis B	0.00531	0.00533	CcSEcCtD
Duloxetine—Influenza—Telbivudine—hepatitis B	0.0053	0.00532	CcSEcCtD
Duloxetine—Oropharyngeal pain—Lamivudine—hepatitis B	0.00523	0.00526	CcSEcCtD
Duloxetine—Hepatitis—Entecavir—hepatitis B	0.00516	0.00519	CcSEcCtD
Duloxetine—Oedema peripheral—Entecavir—hepatitis B	0.00508	0.00511	CcSEcCtD
Duloxetine—Abdominal discomfort—Telbivudine—hepatitis B	0.00508	0.0051	CcSEcCtD
Duloxetine—Hepatitis—Adefovir Dipivoxil—hepatitis B	0.00504	0.00506	CcSEcCtD
Duloxetine—Hypercholesterolaemia—Lamivudine—hepatitis B	0.00503	0.00505	CcSEcCtD
Duloxetine—Pharyngitis—Adefovir Dipivoxil—hepatitis B	0.005	0.00502	CcSEcCtD
Duloxetine—Urinary tract disorder—Adefovir Dipivoxil—hepatitis B	0.00497	0.005	CcSEcCtD
Duloxetine—Connective tissue disorder—Adefovir Dipivoxil—hepatitis B	0.00495	0.00497	CcSEcCtD
Duloxetine—Urethral disorder—Adefovir Dipivoxil—hepatitis B	0.00494	0.00496	CcSEcCtD
Duloxetine—Upper respiratory tract infection—Telbivudine—hepatitis B	0.00492	0.00495	CcSEcCtD
Duloxetine—Muscle twitching—Lamivudine—hepatitis B	0.00485	0.00487	CcSEcCtD
Duloxetine—Musculoskeletal pain—Lamivudine—hepatitis B	0.00482	0.00484	CcSEcCtD
Duloxetine—Eructation—Lamivudine—hepatitis B	0.00467	0.0047	CcSEcCtD
Duloxetine—Immune system disorder—Entecavir—hepatitis B	0.00466	0.00468	CcSEcCtD
Duloxetine—Renal failure—Telbivudine—hepatitis B	0.00464	0.00466	CcSEcCtD
Duloxetine—Alopecia—Entecavir—hepatitis B	0.00456	0.00458	CcSEcCtD
Duloxetine—Mental disorder—Entecavir—hepatitis B	0.00452	0.00454	CcSEcCtD
Duloxetine—Malnutrition—Entecavir—hepatitis B	0.00449	0.00451	CcSEcCtD
Duloxetine—Hepatobiliary disease—Telbivudine—hepatitis B	0.00447	0.00449	CcSEcCtD
Duloxetine—Malnutrition—Adefovir Dipivoxil—hepatitis B	0.00438	0.0044	CcSEcCtD
Duloxetine—Flatulence—Adefovir Dipivoxil—hepatitis B	0.00432	0.00434	CcSEcCtD
Duloxetine—Urine output increased—Lamivudine—hepatitis B	0.0043	0.00432	CcSEcCtD
Duloxetine—Back pain—Adefovir Dipivoxil—hepatitis B	0.00424	0.00426	CcSEcCtD
Duloxetine—Hepatitis—Telbivudine—hepatitis B	0.00424	0.00426	CcSEcCtD
Duloxetine—Hypoaesthesia—Telbivudine—hepatitis B	0.00422	0.00424	CcSEcCtD
Duloxetine—Pharyngitis—Telbivudine—hepatitis B	0.00421	0.00423	CcSEcCtD
Duloxetine—Connective tissue disorder—Telbivudine—hepatitis B	0.00417	0.00419	CcSEcCtD
Duloxetine—Anaemia—Adefovir Dipivoxil—hepatitis B	0.00405	0.00407	CcSEcCtD
Duloxetine—Lymphadenopathy—Lamivudine—hepatitis B	0.00405	0.00407	CcSEcCtD
Duloxetine—Leukopenia—Entecavir—hepatitis B	0.00402	0.00404	CcSEcCtD
Duloxetine—Phlebitis—Lamivudine—hepatitis B	0.00401	0.00403	CcSEcCtD
Duloxetine—Sleep disorder—Lamivudine—hepatitis B	0.00399	0.00401	CcSEcCtD
Duloxetine—Polyuria—Lamivudine—hepatitis B	0.00393	0.00395	CcSEcCtD
Duloxetine—Gastroenteritis—Lamivudine—hepatitis B	0.0039	0.00392	CcSEcCtD
Duloxetine—Cough—Adefovir Dipivoxil—hepatitis B	0.00383	0.00384	CcSEcCtD
Duloxetine—Mediastinal disorder—Telbivudine—hepatitis B	0.00382	0.00384	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Entecavir—hepatitis B	0.0038	0.00382	CcSEcCtD
Duloxetine—Chest pain—Adefovir Dipivoxil—hepatitis B	0.00373	0.00375	CcSEcCtD
Duloxetine—Myalgia—Adefovir Dipivoxil—hepatitis B	0.00373	0.00375	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Adefovir Dipivoxil—hepatitis B	0.00371	0.00372	CcSEcCtD
Duloxetine—Malnutrition—Telbivudine—hepatitis B	0.00369	0.00371	CcSEcCtD
Duloxetine—Anaphylactic shock—Entecavir—hepatitis B	0.00367	0.00368	CcSEcCtD
Duloxetine—Infection—Entecavir—hepatitis B	0.00364	0.00366	CcSEcCtD
Duloxetine—Thirst—Lamivudine—hepatitis B	0.00363	0.00365	CcSEcCtD
Duloxetine—Renal impairment—Lamivudine—hepatitis B	0.00363	0.00365	CcSEcCtD
Duloxetine—Dysgeusia—Telbivudine—hepatitis B	0.00361	0.00363	CcSEcCtD
Duloxetine—Nervous system disorder—Entecavir—hepatitis B	0.0036	0.00361	CcSEcCtD
Duloxetine—Back pain—Telbivudine—hepatitis B	0.00357	0.00359	CcSEcCtD
Duloxetine—Skin disorder—Entecavir—hepatitis B	0.00356	0.00358	CcSEcCtD
Duloxetine—Muscle spasms—Telbivudine—hepatitis B	0.00355	0.00357	CcSEcCtD
Duloxetine—Hypoglycaemia—Lamivudine—hepatitis B	0.00354	0.00356	CcSEcCtD
Duloxetine—Nervous system disorder—Adefovir Dipivoxil—hepatitis B	0.00351	0.00353	CcSEcCtD
Duloxetine—Thrombocytopenia—Adefovir Dipivoxil—hepatitis B	0.0035	0.00352	CcSEcCtD
Duloxetine—Skin disorder—Adefovir Dipivoxil—hepatitis B	0.00348	0.00349	CcSEcCtD
Duloxetine—Ill-defined disorder—Telbivudine—hepatitis B	0.00342	0.00344	CcSEcCtD
Duloxetine—Anorexia—Adefovir Dipivoxil—hepatitis B	0.00341	0.00343	CcSEcCtD
Duloxetine—Migraine—Lamivudine—hepatitis B	0.0034	0.00342	CcSEcCtD
Duloxetine—Affect lability—Lamivudine—hepatitis B	0.0034	0.00342	CcSEcCtD
Duloxetine—Malaise—Telbivudine—hepatitis B	0.00333	0.00334	CcSEcCtD
Duloxetine—Insomnia—Entecavir—hepatitis B	0.00332	0.00333	CcSEcCtD
Duloxetine—Mood swings—Lamivudine—hepatitis B	0.00327	0.00329	CcSEcCtD
Duloxetine—Somnolence—Entecavir—hepatitis B	0.00326	0.00328	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Adefovir Dipivoxil—hepatitis B	0.00326	0.00327	CcSEcCtD
Duloxetine—Dyspepsia—Entecavir—hepatitis B	0.00323	0.00324	CcSEcCtD
Duloxetine—Cough—Telbivudine—hepatitis B	0.00322	0.00324	CcSEcCtD
Duloxetine—Dehydration—Lamivudine—hepatitis B	0.00321	0.00323	CcSEcCtD
Duloxetine—Liver function test abnormal—Lamivudine—hepatitis B	0.00319	0.0032	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Entecavir—hepatitis B	0.00317	0.00318	CcSEcCtD
Duloxetine—Fatigue—Entecavir—hepatitis B	0.00316	0.00318	CcSEcCtD
Duloxetine—Abdominal pain upper—Lamivudine—hepatitis B	0.00315	0.00317	CcSEcCtD
Duloxetine—Dyspepsia—Adefovir Dipivoxil—hepatitis B	0.00315	0.00316	CcSEcCtD
Duloxetine—Arthralgia—Telbivudine—hepatitis B	0.00314	0.00316	CcSEcCtD
Duloxetine—Chest pain—Telbivudine—hepatitis B	0.00314	0.00316	CcSEcCtD
Duloxetine—Myalgia—Telbivudine—hepatitis B	0.00314	0.00316	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Telbivudine—hepatitis B	0.00312	0.00314	CcSEcCtD
Duloxetine—Aspartate aminotransferase increased—Lamivudine—hepatitis B	0.00311	0.00312	CcSEcCtD
Duloxetine—Cramp muscle—Lamivudine—hepatitis B	0.00311	0.00312	CcSEcCtD
Duloxetine—Decreased appetite—Adefovir Dipivoxil—hepatitis B	0.00311	0.00312	CcSEcCtD
Duloxetine—Discomfort—Telbivudine—hepatitis B	0.0031	0.00312	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Adefovir Dipivoxil—hepatitis B	0.00309	0.0031	CcSEcCtD
Duloxetine—Nasopharyngitis—Lamivudine—hepatitis B	0.00309	0.0031	CcSEcCtD
Duloxetine—Muscular weakness—Lamivudine—hepatitis B	0.00305	0.00306	CcSEcCtD
Duloxetine—Alanine aminotransferase increased—Lamivudine—hepatitis B	0.00305	0.00306	CcSEcCtD
Duloxetine—Gastrointestinal pain—Entecavir—hepatitis B	0.003	0.00301	CcSEcCtD
Duloxetine—Influenza—Lamivudine—hepatitis B	0.00299	0.003	CcSEcCtD
Duloxetine—Dysphagia—Lamivudine—hepatitis B	0.00299	0.003	CcSEcCtD
Duloxetine—Nervous system disorder—Telbivudine—hepatitis B	0.00295	0.00297	CcSEcCtD
Duloxetine—Thrombocytopenia—Telbivudine—hepatitis B	0.00295	0.00296	CcSEcCtD
Duloxetine—Pancreatitis—Lamivudine—hepatitis B	0.00293	0.00294	CcSEcCtD
Duloxetine—Skin disorder—Telbivudine—hepatitis B	0.00293	0.00294	CcSEcCtD
Duloxetine—Gastrointestinal pain—Adefovir Dipivoxil—hepatitis B	0.00293	0.00294	CcSEcCtD
Duloxetine—Sweating increased—Lamivudine—hepatitis B	0.00291	0.00292	CcSEcCtD
Duloxetine—Body temperature increased—Entecavir—hepatitis B	0.0029	0.00291	CcSEcCtD
Duloxetine—Abdominal pain—Entecavir—hepatitis B	0.0029	0.00291	CcSEcCtD
Duloxetine—Abdominal discomfort—Lamivudine—hepatitis B	0.00286	0.00288	CcSEcCtD
Duloxetine—Abdominal pain—Adefovir Dipivoxil—hepatitis B	0.00283	0.00284	CcSEcCtD
Duloxetine—Body temperature increased—Adefovir Dipivoxil—hepatitis B	0.00283	0.00284	CcSEcCtD
Duloxetine—Dysuria—Lamivudine—hepatitis B	0.00279	0.0028	CcSEcCtD
Duloxetine—Pollakiuria—Lamivudine—hepatitis B	0.00276	0.00277	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Telbivudine—hepatitis B	0.00274	0.00276	CcSEcCtD
Duloxetine—Insomnia—Telbivudine—hepatitis B	0.00272	0.00274	CcSEcCtD
Duloxetine—Paraesthesia—Telbivudine—hepatitis B	0.0027	0.00272	CcSEcCtD
Duloxetine—Hyperglycaemia—Lamivudine—hepatitis B	0.00269	0.00271	CcSEcCtD
Duloxetine—Dyspepsia—Telbivudine—hepatitis B	0.00265	0.00266	CcSEcCtD
Duloxetine—Stevens-Johnson syndrome—Lamivudine—hepatitis B	0.00264	0.00265	CcSEcCtD
Duloxetine—Asthenia—Entecavir—hepatitis B	0.00263	0.00264	CcSEcCtD
Duloxetine—Renal failure—Lamivudine—hepatitis B	0.00262	0.00263	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Telbivudine—hepatitis B	0.0026	0.00261	CcSEcCtD
Duloxetine—Fatigue—Telbivudine—hepatitis B	0.0026	0.00261	CcSEcCtD
Duloxetine—Stomatitis—Lamivudine—hepatitis B	0.00259	0.00261	CcSEcCtD
Duloxetine—Jaundice—Lamivudine—hepatitis B	0.00259	0.00261	CcSEcCtD
Duloxetine—Pain—Telbivudine—hepatitis B	0.00258	0.00259	CcSEcCtD
Duloxetine—Asthenia—Adefovir Dipivoxil—hepatitis B	0.00257	0.00258	CcSEcCtD
Duloxetine—Pruritus—Adefovir Dipivoxil—hepatitis B	0.00253	0.00254	CcSEcCtD
Duloxetine—Hepatobiliary disease—Lamivudine—hepatitis B	0.00252	0.00253	CcSEcCtD
Duloxetine—Epistaxis—Lamivudine—hepatitis B	0.00251	0.00252	CcSEcCtD
Duloxetine—Diarrhoea—Entecavir—hepatitis B	0.00251	0.00252	CcSEcCtD
Duloxetine—Feeling abnormal—Telbivudine—hepatitis B	0.00248	0.00249	CcSEcCtD
Duloxetine—Gastrointestinal pain—Telbivudine—hepatitis B	0.00246	0.00247	CcSEcCtD
Duloxetine—Diarrhoea—Adefovir Dipivoxil—hepatitis B	0.00245	0.00246	CcSEcCtD
Duloxetine—Dizziness—Entecavir—hepatitis B	0.00242	0.00244	CcSEcCtD
Duloxetine—Hepatitis—Lamivudine—hepatitis B	0.00239	0.0024	CcSEcCtD
Duloxetine—Abdominal pain—Telbivudine—hepatitis B	0.00238	0.00239	CcSEcCtD
Duloxetine—Body temperature increased—Telbivudine—hepatitis B	0.00238	0.00239	CcSEcCtD
Duloxetine—Hypoaesthesia—Lamivudine—hepatitis B	0.00238	0.00239	CcSEcCtD
Duloxetine—Pharyngitis—Lamivudine—hepatitis B	0.00237	0.00238	CcSEcCtD
Duloxetine—Connective tissue disorder—Lamivudine—hepatitis B	0.00235	0.00236	CcSEcCtD
Duloxetine—Vomiting—Entecavir—hepatitis B	0.00233	0.00234	CcSEcCtD
Duloxetine—Rash—Entecavir—hepatitis B	0.00231	0.00232	CcSEcCtD
Duloxetine—Dermatitis—Entecavir—hepatitis B	0.00231	0.00232	CcSEcCtD
Duloxetine—Headache—Entecavir—hepatitis B	0.0023	0.00231	CcSEcCtD
Duloxetine—Vomiting—Adefovir Dipivoxil—hepatitis B	0.00227	0.00229	CcSEcCtD
Duloxetine—Erythema multiforme—Lamivudine—hepatitis B	0.00226	0.00227	CcSEcCtD
Duloxetine—Rash—Adefovir Dipivoxil—hepatitis B	0.00226	0.00227	CcSEcCtD
Duloxetine—Dermatitis—Adefovir Dipivoxil—hepatitis B	0.00225	0.00226	CcSEcCtD
Duloxetine—Headache—Adefovir Dipivoxil—hepatitis B	0.00224	0.00225	CcSEcCtD
Duloxetine—Nausea—Entecavir—hepatitis B	0.00218	0.00219	CcSEcCtD
Duloxetine—Asthenia—Telbivudine—hepatitis B	0.00216	0.00217	CcSEcCtD
Duloxetine—Immune system disorder—Lamivudine—hepatitis B	0.00216	0.00217	CcSEcCtD
Duloxetine—Mediastinal disorder—Lamivudine—hepatitis B	0.00215	0.00216	CcSEcCtD
Duloxetine—Chills—Lamivudine—hepatitis B	0.00214	0.00215	CcSEcCtD
Duloxetine—Pruritus—Telbivudine—hepatitis B	0.00213	0.00214	CcSEcCtD
Duloxetine—Nausea—Adefovir Dipivoxil—hepatitis B	0.00213	0.00214	CcSEcCtD
Duloxetine—Alopecia—Lamivudine—hepatitis B	0.00211	0.00212	CcSEcCtD
Duloxetine—Malnutrition—Lamivudine—hepatitis B	0.00208	0.00209	CcSEcCtD
Duloxetine—Erythema—Lamivudine—hepatitis B	0.00208	0.00209	CcSEcCtD
Duloxetine—Diarrhoea—Telbivudine—hepatitis B	0.00206	0.00207	CcSEcCtD
Duloxetine—Flatulence—Lamivudine—hepatitis B	0.00205	0.00206	CcSEcCtD
Duloxetine—Tension—Lamivudine—hepatitis B	0.00204	0.00205	CcSEcCtD
Duloxetine—Dysgeusia—Lamivudine—hepatitis B	0.00204	0.00205	CcSEcCtD
Duloxetine—Nervousness—Lamivudine—hepatitis B	0.00202	0.00203	CcSEcCtD
Duloxetine—Back pain—Lamivudine—hepatitis B	0.00201	0.00202	CcSEcCtD
Duloxetine—Muscle spasms—Lamivudine—hepatitis B	0.002	0.00201	CcSEcCtD
Duloxetine—Dizziness—Telbivudine—hepatitis B	0.00199	0.002	CcSEcCtD
Duloxetine—Tremor—Lamivudine—hepatitis B	0.00195	0.00196	CcSEcCtD
Duloxetine—Ill-defined disorder—Lamivudine—hepatitis B	0.00193	0.00194	CcSEcCtD
Duloxetine—Anaemia—Lamivudine—hepatitis B	0.00192	0.00193	CcSEcCtD
Duloxetine—Vomiting—Telbivudine—hepatitis B	0.00192	0.00192	CcSEcCtD
Duloxetine—Angioedema—Lamivudine—hepatitis B	0.0019	0.00191	CcSEcCtD
Duloxetine—Rash—Telbivudine—hepatitis B	0.0019	0.00191	CcSEcCtD
Duloxetine—Dermatitis—Telbivudine—hepatitis B	0.0019	0.00191	CcSEcCtD
Duloxetine—Headache—Telbivudine—hepatitis B	0.00189	0.0019	CcSEcCtD
Duloxetine—Malaise—Lamivudine—hepatitis B	0.00188	0.00188	CcSEcCtD
Duloxetine—Vertigo—Lamivudine—hepatitis B	0.00187	0.00188	CcSEcCtD
Duloxetine—Syncope—Lamivudine—hepatitis B	0.00187	0.00187	CcSEcCtD
Duloxetine—Leukopenia—Lamivudine—hepatitis B	0.00186	0.00187	CcSEcCtD
Duloxetine—Loss of consciousness—Lamivudine—hepatitis B	0.00183	0.00184	CcSEcCtD
Duloxetine—Cough—Lamivudine—hepatitis B	0.00182	0.00182	CcSEcCtD
Duloxetine—Convulsion—Lamivudine—hepatitis B	0.0018	0.00181	CcSEcCtD
Duloxetine—Nausea—Telbivudine—hepatitis B	0.00179	0.0018	CcSEcCtD
Duloxetine—Arthralgia—Lamivudine—hepatitis B	0.00177	0.00178	CcSEcCtD
Duloxetine—Chest pain—Lamivudine—hepatitis B	0.00177	0.00178	CcSEcCtD
Duloxetine—Myalgia—Lamivudine—hepatitis B	0.00177	0.00178	CcSEcCtD
Duloxetine—Anxiety—Lamivudine—hepatitis B	0.00176	0.00177	CcSEcCtD
Duloxetine—Unspecified disorder of skin and subcutaneous tissue—Lamivudine—hepatitis B	0.00176	0.00177	CcSEcCtD
Duloxetine—Discomfort—Lamivudine—hepatitis B	0.00175	0.00176	CcSEcCtD
Duloxetine—Dry mouth—Lamivudine—hepatitis B	0.00173	0.00174	CcSEcCtD
Duloxetine—Confusional state—Lamivudine—hepatitis B	0.00171	0.00172	CcSEcCtD
Duloxetine—Anaphylactic shock—Lamivudine—hepatitis B	0.0017	0.00171	CcSEcCtD
Duloxetine—Oedema—Lamivudine—hepatitis B	0.0017	0.00171	CcSEcCtD
Duloxetine—Infection—Lamivudine—hepatitis B	0.00169	0.00169	CcSEcCtD
Duloxetine—Shock—Lamivudine—hepatitis B	0.00167	0.00168	CcSEcCtD
Duloxetine—Nervous system disorder—Lamivudine—hepatitis B	0.00166	0.00167	CcSEcCtD
Duloxetine—Thrombocytopenia—Lamivudine—hepatitis B	0.00166	0.00167	CcSEcCtD
Duloxetine—Skin disorder—Lamivudine—hepatitis B	0.00165	0.00166	CcSEcCtD
Duloxetine—Hyperhidrosis—Lamivudine—hepatitis B	0.00164	0.00165	CcSEcCtD
Duloxetine—Anorexia—Lamivudine—hepatitis B	0.00162	0.00163	CcSEcCtD
Duloxetine—Musculoskeletal discomfort—Lamivudine—hepatitis B	0.00155	0.00155	CcSEcCtD
Duloxetine—Insomnia—Lamivudine—hepatitis B	0.00154	0.00154	CcSEcCtD
Duloxetine—Paraesthesia—Lamivudine—hepatitis B	0.00152	0.00153	CcSEcCtD
Duloxetine—Somnolence—Lamivudine—hepatitis B	0.00151	0.00152	CcSEcCtD
Duloxetine—Dyspepsia—Lamivudine—hepatitis B	0.00149	0.0015	CcSEcCtD
Duloxetine—Decreased appetite—Lamivudine—hepatitis B	0.00148	0.00148	CcSEcCtD
Duloxetine—Gastrointestinal disorder—Lamivudine—hepatitis B	0.00147	0.00147	CcSEcCtD
Duloxetine—Fatigue—Lamivudine—hepatitis B	0.00146	0.00147	CcSEcCtD
Duloxetine—Pain—Lamivudine—hepatitis B	0.00145	0.00146	CcSEcCtD
Duloxetine—Constipation—Lamivudine—hepatitis B	0.00145	0.00146	CcSEcCtD
Duloxetine—Feeling abnormal—Lamivudine—hepatitis B	0.0014	0.00141	CcSEcCtD
Duloxetine—Gastrointestinal pain—Lamivudine—hepatitis B	0.00139	0.00139	CcSEcCtD
Duloxetine—Urticaria—Lamivudine—hepatitis B	0.00135	0.00135	CcSEcCtD
Duloxetine—Abdominal pain—Lamivudine—hepatitis B	0.00134	0.00135	CcSEcCtD
Duloxetine—Body temperature increased—Lamivudine—hepatitis B	0.00134	0.00135	CcSEcCtD
Duloxetine—Hypersensitivity—Lamivudine—hepatitis B	0.00125	0.00126	CcSEcCtD
Duloxetine—Asthenia—Lamivudine—hepatitis B	0.00122	0.00122	CcSEcCtD
Duloxetine—Pruritus—Lamivudine—hepatitis B	0.0012	0.00121	CcSEcCtD
Duloxetine—Diarrhoea—Lamivudine—hepatitis B	0.00116	0.00117	CcSEcCtD
Duloxetine—Dizziness—Lamivudine—hepatitis B	0.00112	0.00113	CcSEcCtD
Duloxetine—Vomiting—Lamivudine—hepatitis B	0.00108	0.00108	CcSEcCtD
Duloxetine—Rash—Lamivudine—hepatitis B	0.00107	0.00108	CcSEcCtD
Duloxetine—Dermatitis—Lamivudine—hepatitis B	0.00107	0.00107	CcSEcCtD
Duloxetine—Headache—Lamivudine—hepatitis B	0.00106	0.00107	CcSEcCtD
Duloxetine—Nausea—Lamivudine—hepatitis B	0.00101	0.00101	CcSEcCtD
Duloxetine—SLC6A3—Alpha-synuclein signaling—UBE2L3—hepatitis B	0.000249	0.0534	CbGpPWpGaD
Duloxetine—SLC6A3—Parkinsons Disease Pathway—UBE2L3—hepatitis B	0.000212	0.0453	CbGpPWpGaD
Duloxetine—CYP1A2—Estrogen Receptor Pathway—NR0B2—hepatitis B	0.000168	0.0361	CbGpPWpGaD
Duloxetine—CYP2D6—CYP2E1 reactions—CYP2A6—hepatitis B	0.000148	0.0317	CbGpPWpGaD
Duloxetine—NPY1R—Peptide GPCRs—CCR5—hepatitis B	0.000134	0.0288	CbGpPWpGaD
Duloxetine—CYP1A2—Aflatoxin activation and detoxification—GGT2—hepatitis B	0.000134	0.0286	CbGpPWpGaD
Duloxetine—CYP2D6—Fatty Acid Omega Oxidation—CYP2A6—hepatitis B	0.00011	0.0235	CbGpPWpGaD
Duloxetine—CYP1A2—Fatty Acid Omega Oxidation—CYP2A6—hepatitis B	9.29e-05	0.0199	CbGpPWpGaD
Duloxetine—CYP2D6—Xenobiotics—CYP2A6—hepatitis B	9.17e-05	0.0197	CbGpPWpGaD
Duloxetine—CYP2D6—Tamoxifen metabolism—CYP2A6—hepatitis B	8.82e-05	0.0189	CbGpPWpGaD
Duloxetine—SLC6A4—NRF2 pathway—GGT2—hepatitis B	8.65e-05	0.0185	CbGpPWpGaD
Duloxetine—NPY1R—Peptide ligand-binding receptors—CXCL10—hepatitis B	8.14e-05	0.0174	CbGpPWpGaD
Duloxetine—CYP1A2—Xenobiotics—CYP2A6—hepatitis B	7.77e-05	0.0167	CbGpPWpGaD
Duloxetine—CYP1A2—Tamoxifen metabolism—CYP2A6—hepatitis B	7.47e-05	0.016	CbGpPWpGaD
Duloxetine—SLC6A2—NRF2 pathway—GGT2—hepatitis B	7.44e-05	0.0159	CbGpPWpGaD
Duloxetine—NPY1R—G alpha (i) signalling events—CXCL10—hepatitis B	6.87e-05	0.0147	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—GGT2—hepatitis B	6.59e-05	0.0141	CbGpPWpGaD
Duloxetine—CYP1A2—Aflatoxin activation and detoxification—GGT1—hepatitis B	6.32e-05	0.0136	CbGpPWpGaD
Duloxetine—NPY1R—Peptide ligand-binding receptors—CCR5—hepatitis B	6.31e-05	0.0135	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CXCL10—hepatitis B	5.46e-05	0.0117	CbGpPWpGaD
Duloxetine—NPY1R—Peptide ligand-binding receptors—F2—hepatitis B	5.42e-05	0.0116	CbGpPWpGaD
Duloxetine—SLC6A3—Neuronal System—KCNH1—hepatitis B	5.4e-05	0.0116	CbGpPWpGaD
Duloxetine—NPY1R—G alpha (i) signalling events—CCR5—hepatitis B	5.33e-05	0.0114	CbGpPWpGaD
Duloxetine—SLC6A4—NRF2 pathway—CYP2A6—hepatitis B	5.24e-05	0.0112	CbGpPWpGaD
Duloxetine—NPY1R—GPCRs, Class A Rhodopsin-like—CCR5—hepatitis B	4.94e-05	0.0106	CbGpPWpGaD
Duloxetine—SLC6A2—NRF2 pathway—CYP2A6—hepatitis B	4.51e-05	0.00966	CbGpPWpGaD
Duloxetine—SLC6A4—Monoamine Transport—TNF—hepatitis B	4.33e-05	0.00928	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—CCR5—hepatitis B	4.23e-05	0.00908	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—CXCL10—hepatitis B	4.16e-05	0.00891	CbGpPWpGaD
Duloxetine—SLC6A4—NRF2 pathway—GGT1—hepatitis B	4.09e-05	0.00877	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—CYP2A6—hepatitis B	3.99e-05	0.00856	CbGpPWpGaD
Duloxetine—CYP1A2—Phase II conjugation—GGT2—hepatitis B	3.92e-05	0.0084	CbGpPWpGaD
Duloxetine—CYP2D6—Cytochrome P450 - arranged by substrate type—CYP2A6—hepatitis B	3.81e-05	0.00817	CbGpPWpGaD
Duloxetine—CYP2D6—Oxidation by Cytochrome P450—CYP2A6—hepatitis B	3.76e-05	0.00806	CbGpPWpGaD
Duloxetine—SLC6A2—Monoamine Transport—TNF—hepatitis B	3.72e-05	0.00798	CbGpPWpGaD
Duloxetine—SLC6A3—Dopaminergic Neurogenesis—TGFB1—hepatitis B	3.72e-05	0.00797	CbGpPWpGaD
Duloxetine—NPY1R—Class A/1 (Rhodopsin-like receptors)—F2—hepatitis B	3.63e-05	0.00779	CbGpPWpGaD
Duloxetine—SLC6A2—NRF2 pathway—GGT1—hepatitis B	3.52e-05	0.00754	CbGpPWpGaD
Duloxetine—SLC6A3—Monoamine Transport—TNF—hepatitis B	3.3e-05	0.00707	CbGpPWpGaD
Duloxetine—CYP1A2—Cytochrome P450 - arranged by substrate type—CYP2A6—hepatitis B	3.23e-05	0.00692	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—CCR5—hepatitis B	3.22e-05	0.00691	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL10—hepatitis B	3.2e-05	0.00687	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—RIT2—hepatitis B	3.19e-05	0.00684	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—SAG—hepatitis B	3.19e-05	0.00684	CbGpPWpGaD
Duloxetine—CYP1A2—Oxidation by Cytochrome P450—CYP2A6—hepatitis B	3.19e-05	0.00683	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—GGT1—hepatitis B	3.12e-05	0.00668	CbGpPWpGaD
Duloxetine—CYP2D6—Phase 1 - Functionalization of compounds—CYP2A6—hepatitis B	3.09e-05	0.00662	CbGpPWpGaD
Duloxetine—CYP1A2—Arachidonic acid metabolism—GGT1—hepatitis B	2.92e-05	0.00625	CbGpPWpGaD
Duloxetine—CYP2D6—Metapathway biotransformation—AKR1B1—hepatitis B	2.79e-05	0.00597	CbGpPWpGaD
Duloxetine—NPY1R—GPCR ligand binding—F2—hepatitis B	2.77e-05	0.00593	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—GGT2—hepatitis B	2.71e-05	0.0058	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Other—CCR5—hepatitis B	2.68e-05	0.00575	CbGpPWpGaD
Duloxetine—CYP1A2—Phase 1 - Functionalization of compounds—CYP2A6—hepatitis B	2.62e-05	0.00561	CbGpPWpGaD
Duloxetine—CYP1A2—Metapathway biotransformation—AKR1B1—hepatitis B	2.36e-05	0.00506	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—CXCL10—hepatitis B	2.35e-05	0.00504	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—FAS—hepatitis B	2.34e-05	0.00503	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—GGT2—hepatitis B	2.29e-05	0.00492	CbGpPWpGaD
Duloxetine—CYP2D6—Melatonin metabolism and effects—NFKB1—hepatitis B	2.15e-05	0.00461	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CXCL10—hepatitis B	2.13e-05	0.00457	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CXCL10—hepatitis B	2.01e-05	0.00432	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—NOS2—hepatitis B	2.01e-05	0.0043	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL10—hepatitis B	1.93e-05	0.00413	CbGpPWpGaD
Duloxetine—CYP1A2—Phase II conjugation—GGT1—hepatitis B	1.85e-05	0.00398	CbGpPWpGaD
Duloxetine—HTR6—GPCRs, Class A Rhodopsin-like—CCR5—hepatitis B	1.82e-05	0.00391	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—CCR5—hepatitis B	1.82e-05	0.00391	CbGpPWpGaD
Duloxetine—CYP1A2—Melatonin metabolism and effects—NFKB1—hepatitis B	1.82e-05	0.0039	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—CCR5—hepatitis B	1.65e-05	0.00355	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—CYP2A6—hepatitis B	1.64e-05	0.00352	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—CTNNB1—hepatitis B	1.62e-05	0.00346	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—NFKB1—hepatitis B	1.57e-05	0.00336	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—F2—hepatitis B	1.56e-05	0.00335	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—CCR5—hepatitis B	1.56e-05	0.00335	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CXCL10—hepatitis B	1.53e-05	0.00329	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IFNG—hepatitis B	1.51e-05	0.00324	CbGpPWpGaD
Duloxetine—HTR2C—G alpha (q) signalling events—F2—hepatitis B	1.49e-05	0.00319	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CXCL10—hepatitis B	1.48e-05	0.00318	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—F2—hepatitis B	1.42e-05	0.00304	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—CYP2A6—hepatitis B	1.39e-05	0.00298	CbGpPWpGaD
Duloxetine—SLC6A4—NRF2 pathway—TGFB1—hepatitis B	1.38e-05	0.00295	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—IL2—hepatitis B	1.34e-05	0.00288	CbGpPWpGaD
Duloxetine—HTR2C—GPCRs, Class A Rhodopsin-like—CCR5—hepatitis B	1.34e-05	0.00288	CbGpPWpGaD
Duloxetine—HTR6—Class A/1 (Rhodopsin-like receptors)—F2—hepatitis B	1.34e-05	0.00287	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—F2—hepatitis B	1.33e-05	0.00286	CbGpPWpGaD
Duloxetine—HTR2A—G alpha (q) signalling events—F2—hepatitis B	1.29e-05	0.00277	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CXCL10—hepatitis B	1.29e-05	0.00276	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—PTEN—hepatitis B	1.29e-05	0.00276	CbGpPWpGaD
Duloxetine—CYP2D6—Biological oxidations—GGT1—hepatitis B	1.28e-05	0.00275	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—CDKN1A—hepatitis B	1.27e-05	0.00272	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CXCL10—hepatitis B	1.26e-05	0.0027	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—NFKB1—hepatitis B	1.26e-05	0.0027	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—TNF—hepatitis B	1.22e-05	0.00261	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—CCR5—hepatitis B	1.19e-05	0.00255	CbGpPWpGaD
Duloxetine—SLC6A2—NRF2 pathway—TGFB1—hepatitis B	1.18e-05	0.00254	CbGpPWpGaD
Duloxetine—SLC6A2—SLC-mediated transmembrane transport—ALB—hepatitis B	1.18e-05	0.00253	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—RIT2—hepatitis B	1.18e-05	0.00252	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—SAG—hepatitis B	1.18e-05	0.00252	CbGpPWpGaD
Duloxetine—HTR2A—GPCRs, Class A Rhodopsin-like—CCR5—hepatitis B	1.17e-05	0.0025	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—F2—hepatitis B	1.16e-05	0.00248	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—CCR5—hepatitis B	1.15e-05	0.00247	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CXCL10—hepatitis B	1.13e-05	0.00242	CbGpPWpGaD
Duloxetine—CYP1A2—Biological oxidations—GGT1—hepatitis B	1.08e-05	0.00233	CbGpPWpGaD
Duloxetine—NPY1R—GPCR downstream signaling—IL2—hepatitis B	1.05e-05	0.00226	CbGpPWpGaD
Duloxetine—SLC6A3—NRF2 pathway—TGFB1—hepatitis B	1.05e-05	0.00225	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TGFB1—hepatitis B	1.05e-05	0.00225	CbGpPWpGaD
Duloxetine—SLC6A3—SLC-mediated transmembrane transport—ALB—hepatitis B	1.04e-05	0.00224	CbGpPWpGaD
Duloxetine—HTR6—GPCR ligand binding—F2—hepatitis B	1.02e-05	0.00219	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—CCR5—hepatitis B	9.99e-06	0.00214	CbGpPWpGaD
Duloxetine—HTR2C—Class A/1 (Rhodopsin-like receptors)—F2—hepatitis B	9.87e-06	0.00212	CbGpPWpGaD
Duloxetine—SLC6A4—SIDS Susceptibility Pathways—IL6—hepatitis B	9.84e-06	0.00211	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CXCL10—hepatitis B	9.81e-06	0.0021	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor Pathway—TNF—hepatitis B	9.79e-06	0.0021	CbGpPWpGaD
Duloxetine—CYP1A2—Aryl Hydrocarbon Receptor—TNF—hepatitis B	9.79e-06	0.0021	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CCR5—hepatitis B	9.78e-06	0.0021	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—CTNNB1—hepatitis B	9.73e-06	0.00208	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL2—hepatitis B	9.56e-06	0.00205	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—NFKB1—hepatitis B	9.43e-06	0.00202	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—AKR1B1—hepatitis B	9.19e-06	0.00197	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—TP53—hepatitis B	8.78e-06	0.00188	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—CCR5—hepatitis B	8.76e-06	0.00188	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—SAG—hepatitis B	8.68e-06	0.00186	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—RIT2—hepatitis B	8.68e-06	0.00186	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CXCL10—hepatitis B	8.67e-06	0.00186	CbGpPWpGaD
Duloxetine—HTR2A—Class A/1 (Rhodopsin-like receptors)—F2—hepatitis B	8.57e-06	0.00184	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—F2—hepatitis B	8.39e-06	0.0018	CbGpPWpGaD
Duloxetine—SLC6A4—Circadian rythm related genes—IL6—hepatitis B	8.03e-06	0.00172	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CXCL10—hepatitis B	7.87e-06	0.00169	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—CCR5—hepatitis B	7.61e-06	0.00163	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—RIT2—hepatitis B	7.53e-06	0.00161	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—SAG—hepatitis B	7.53e-06	0.00161	CbGpPWpGaD
Duloxetine—HTR2C—GPCR ligand binding—F2—hepatitis B	7.52e-06	0.00161	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—TNF—hepatitis B	7.34e-06	0.00157	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—CCR5—hepatitis B	6.72e-06	0.00144	CbGpPWpGaD
Duloxetine—HTR2A—GPCR ligand binding—F2—hepatitis B	6.53e-06	0.0014	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CXCL10—hepatitis B	6.38e-06	0.00137	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—CCR5—hepatitis B	6.1e-06	0.00131	CbGpPWpGaD
Duloxetine—SLC6A2—Transmembrane transport of small molecules—ALB—hepatitis B	5.99e-06	0.00128	CbGpPWpGaD
Duloxetine—HTR2A—SIDS Susceptibility Pathways—IL6—hepatitis B	5.92e-06	0.00127	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CXCL10—hepatitis B	5.8e-06	0.00124	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—F2—hepatitis B	5.77e-06	0.00124	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL2—hepatitis B	5.65e-06	0.00121	CbGpPWpGaD
Duloxetine—NPY1R—Signaling by GPCR—IL6—hepatitis B	5.62e-06	0.0012	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CXCL10—hepatitis B	5.54e-06	0.00119	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CTNNB1—hepatitis B	5.45e-06	0.00117	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—CDKN1A—hepatitis B	5.33e-06	0.00114	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—PTEN—hepatitis B	5.31e-06	0.00114	CbGpPWpGaD
Duloxetine—SLC6A3—Transmembrane transport of small molecules—ALB—hepatitis B	5.31e-06	0.00114	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—NFKB1—hepatitis B	5.29e-06	0.00113	CbGpPWpGaD
Duloxetine—HTR2C—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—hepatitis B	5.28e-06	0.00113	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—F2—hepatitis B	5.24e-06	0.00112	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CXCL10—hepatitis B	5.03e-06	0.00108	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—CCR5—hepatitis B	4.95e-06	0.00106	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—AKR1B1—hepatitis B	4.83e-06	0.00104	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CXCL10—hepatitis B	4.65e-06	0.000997	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GGT2—hepatitis B	4.63e-06	0.000993	CbGpPWpGaD
Duloxetine—HTR2A—Gastrin-CREB signalling pathway via PKC and MAPK—IL6—hepatitis B	4.58e-06	0.000982	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—CCR5—hepatitis B	4.5e-06	0.000964	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TGFB1—hepatitis B	4.41e-06	0.000944	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—CCR5—hepatitis B	4.3e-06	0.000921	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—F2—hepatitis B	4.25e-06	0.00091	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—GGT1—hepatitis B	4.17e-06	0.000893	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—AKR1B1—hepatitis B	4.09e-06	0.000877	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GGT2—hepatitis B	3.92e-06	0.000841	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—CCR5—hepatitis B	3.9e-06	0.000837	CbGpPWpGaD
Duloxetine—HTR6—GPCR downstream signaling—IL2—hepatitis B	3.88e-06	0.000833	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—F2—hepatitis B	3.86e-06	0.000827	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—F2—hepatitis B	3.69e-06	0.000791	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—TP53—hepatitis B	3.63e-06	0.000777	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CCR5—hepatitis B	3.61e-06	0.000773	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL2—hepatitis B	3.53e-06	0.000756	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CXCL10—hepatitis B	3.42e-06	0.000734	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—F2—hepatitis B	3.35e-06	0.000718	CbGpPWpGaD
Duloxetine—NPY1R—Signaling Pathways—IL6—hepatitis B	3.32e-06	0.000712	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—F2—hepatitis B	3.09e-06	0.000663	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CXCL10—hepatitis B	2.97e-06	0.000637	CbGpPWpGaD
Duloxetine—HTR2C—GPCR downstream signaling—IL2—hepatitis B	2.86e-06	0.000613	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—CYP2A6—hepatitis B	2.81e-06	0.000601	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CCR5—hepatitis B	2.66e-06	0.000569	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL2—hepatitis B	2.6e-06	0.000557	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GOT2—hepatitis B	2.54e-06	0.000544	CbGpPWpGaD
Duloxetine—HTR2A—GPCR downstream signaling—IL2—hepatitis B	2.48e-06	0.000532	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—CYP2A6—hepatitis B	2.38e-06	0.000509	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CCR5—hepatitis B	2.31e-06	0.000494	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—F2—hepatitis B	2.28e-06	0.000488	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL2—hepatitis B	2.26e-06	0.000483	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—ALB—hepatitis B	2.22e-06	0.000475	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GGT1—hepatitis B	2.19e-06	0.000469	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—GOT1—hepatitis B	2.19e-06	0.000469	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GOT2—hepatitis B	2.15e-06	0.000461	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL2—hepatitis B	2.08e-06	0.000447	CbGpPWpGaD
Duloxetine—HTR6—Signaling by GPCR—IL6—hepatitis B	2.07e-06	0.000444	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CTNNB1—hepatitis B	2.01e-06	0.000431	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—F2—hepatitis B	1.98e-06	0.000424	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—CDKN1A—hepatitis B	1.96e-06	0.000421	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—PTEN—hepatitis B	1.96e-06	0.00042	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—NFKB1—hepatitis B	1.95e-06	0.000418	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GGT1—hepatitis B	1.86e-06	0.000398	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—GOT1—hepatitis B	1.86e-06	0.000398	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism of lipids and lipoproteins—PTEN—hepatitis B	1.69e-06	0.000362	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TGFB1—hepatitis B	1.63e-06	0.000348	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL2—hepatitis B	1.53e-06	0.000329	CbGpPWpGaD
Duloxetine—HTR2C—Signaling by GPCR—IL6—hepatitis B	1.53e-06	0.000327	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CTNNB1—hepatitis B	1.48e-06	0.000317	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—CDKN1A—hepatitis B	1.45e-06	0.00031	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—PTEN—hepatitis B	1.44e-06	0.000309	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—NFKB1—hepatitis B	1.44e-06	0.000308	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—TP53—hepatitis B	1.34e-06	0.000287	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL2—hepatitis B	1.33e-06	0.000286	CbGpPWpGaD
Duloxetine—HTR2A—Signaling by GPCR—IL6—hepatitis B	1.33e-06	0.000284	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CTNNB1—hepatitis B	1.29e-06	0.000276	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—CDKN1A—hepatitis B	1.26e-06	0.000269	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—PTEN—hepatitis B	1.25e-06	0.000269	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—NFKB1—hepatitis B	1.25e-06	0.000267	CbGpPWpGaD
Duloxetine—HTR6—Signaling Pathways—IL6—hepatitis B	1.22e-06	0.000263	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TGFB1—hepatitis B	1.2e-06	0.000257	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—ALB—hepatitis B	1.17e-06	0.00025	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TGFB1—hepatitis B	1.04e-06	0.000223	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—ALB—hepatitis B	9.87e-07	0.000212	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—TP53—hepatitis B	9.85e-07	0.000211	CbGpPWpGaD
Duloxetine—HTR2C—Signaling Pathways—IL6—hepatitis B	9.02e-07	0.000193	CbGpPWpGaD
Duloxetine—CYP2D6—Metabolism—PTEN—hepatitis B	8.89e-07	0.000191	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—TP53—hepatitis B	8.56e-07	0.000183	CbGpPWpGaD
Duloxetine—HTR2A—Signaling Pathways—IL6—hepatitis B	7.83e-07	0.000168	CbGpPWpGaD
Duloxetine—CYP1A2—Metabolism—PTEN—hepatitis B	7.53e-07	0.000161	CbGpPWpGaD
